Pfizer, BioNTech report positive early data from phase 2/3 trial of Omicron BA.4/BA.5-adapted bivalent booster in individuals 18 years and older

Pfizer Inc. and BioNTech SE announced early data from a phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the companies